CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, / science - Science Translational Medicine, Volume 18, Issue 856, July 2026.
AI Summary: Preclinical studies show CAR‑T cells engineered to target mutant calreticulin selectively eliminate disease‑driving clones in xenografts and human organoid models of myelofibrosis. The results reveal a potentially curative approach for a previously intractable mutation‑driven disease, though safety, on‑target effects and clinical translation remain to be rigorously tested.
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Stephanie Gomez / nature - Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with o…
AI Summary: A phase I trial of multi‑antigen‑targeted T cells for aggressive pediatric CNS tumors reported early survival and safety signals, suggesting these engineered cells can engage heterogeneous tumor antigens. Investigators emphasize cautious optimism: encouraging early responses in a dire setting, but longer follow‑up and larger cohorts are needed before this becomes standard‑of‑care.
First use of precision editing to study human embryo development reveals role of master gene
medicalxpress - Research led by the University of Cambridge Loke Center for Trophoblast Research has shown that a genome-editing technique can be used to alter a single gene in human embryonic cells, enabling the study of very early human development in unparalleled deta…
AI Summary: Scientists used precision genome editing in human embryos to identify a 'master' developmental gene that triggers early human development stages. The finding clarifies key molecular steps, offering insights into congenital disorders and embryology, but also reignites ethical debate over experimental editing — cue the lab‑coat philosophers.
Bruce Levine: Ten-Year Outcomes Reinforce the Durability of CD19 CAR T-Cell Therapy
oncodaily - Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, shared a post on X: “NEW – Ten-Year Outcomes after CAR T-Cell Therapy for […]
AI Summary: Long‑term data reveal that CD19 CAR‑T therapy produces durable remissions in a subset of B‑cell lymphoma patients, with ten‑year outcomes reinforcing the treatment's long‑term benefit for some. The findings bolster CAR‑T’s curative potential while underscoring the need to identify who will enjoy durable responses.
In a First, Scientists Precisely Edit Human Embryo Genes
Carl Zimmer / nytimes - Researchers relied on a newer gene-editing technique that may make it possibl to engineer embryos, a prospect that has long alarmed bioethicists.
AI Summary: Researchers report the first precise edits to human embryo genes, demonstrating a technical milestone that immediately reopened the ethical and safety conversation about germline modification. Scientists urge caution, tighter oversight and more study before any clinical application while bioethicists debate whether we’ve crossed a line that’s been long teased in science fiction.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
Stem cells have potent potential for diabetes treatment
medicalxpress - Humans have around 30 trillion cells in our adult bodies. Amazingly, each of these cells came from a handful of about 100 stem cells in the earliest days of development. The ability of these embryonic stem cells to turn into any cell type makes them pluri…
AI Summary: Researchers report stem cell–based approaches can replenish insulin‑producing cells and restore glycemic control in diabetes models, offering a potential path beyond daily insulin injections. Early findings suggest significant therapeutic promise, but scientists stress that safety, durability, and immune‑rejection hurdles must be cleared before these techniques graduate from experimental hope to standard care.
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…
AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.
- CD33‑targeted transplant and post‑transplant maintenance (4)
- Safety and ethical scrutiny of gene editing and gene therapy (3)
- Scaling cell therapy: accreditation and expanding CAR indications (3)
- All Other Stories
CD33‑targeted transplant and post‑transplant maintenance
Safety and ethical scrutiny of gene editing and gene therapy
Scaling cell therapy: accreditation and expanding CAR indications
All Other Stories
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder
Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav / science - Science Translational Medicine, Volume 18, Issue 846, April 2026.
AI Summary: Researchers report that antisense oligonucleotide therapy reversed neurological deficits in mouse models of HNRNPH2‑related neurodevelopmental disorder. The preclinical results provide a targeted mechanism to correct pathogenic RNA processing, moving a once‑untreatable condition toward a plausible therapeutic path — pending the usual caution about translating mice to humans.
Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind
livescience - A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.
AI Summary: A gene therapy for inherited deafness delivered dramatic results, restoring hearing in roughly 90% of treated patients in the largest trial of its kind. Investigators report durable improvements over follow-up, signaling a potential one-time intervention for certain genetic deafness types and challenging the notion that auditory loss is always irreversible. Hope, meet hard data.
- FDA approves first-ever gene therapy for inherited hearing loss (6)
- Primate study finds human-like genetic cause of blindness (1)
- Trial shows durable hearing restored in most patients (3)